TC Biopharm (Holdings) 관리

관리 기준 확인 3/4

TC Biopharm (Holdings) CEO는 Bryan Kobel, Jun2021 에 임명되었습니다 의 임기는 3.42 년입니다. 총 연간 보상은 £ 427.17K, 83.3% 로 구성됩니다. 83.3% 급여 및 16.7% 보너스(회사 주식 및 옵션 포함). 는 $ 1.49K 가치에 해당하는 회사 주식의 0.44% 직접 소유합니다. 1.49K. 경영진과 이사회의 평균 재임 기간은 각각 3.1 년과 2.5 년입니다.

주요 정보

Bryan Kobel

최고 경영자

UK£427.2k

총 보상

CEO 급여 비율	83.3%
CEO 임기	3.4yrs
CEO 소유권	0.4%
경영진 평균 재임 기간	3.1yrs
이사회 평균 재임 기간	2.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Bryan Kobel 의 보수는 TC Biopharm (Holdings) 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-UK£9m
Dec 31 2023	UK£427k	UK£356k	-UK£6m
Sep 30 2023	n/a	n/a	-UK£4m
Jun 30 2023	n/a	n/a	-UK£2m
Mar 31 2023	n/a	n/a	-UK£2m
Dec 31 2022	UK£436k	UK£363k	-UK£1m

보상 대 시장: Bryan 의 총 보상 ($USD 535.27K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 649.07K ).

보상과 수익: Bryan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Bryan Kobel (45 yo)

3.4yrs

테뉴어

UK£427,169

보상

Mr. Bryan Leland Kobel serves as Chief Executive Officer at TC Biopharm Limited. Mr. Kobel serves as Chief Executive Officer of TC Biopharm (Holdings) Plc since June 2021 and serves as Director. He joined...

리더십 팀

이름	위치	테뉴어	보상	소유권
Bryan Kobel	CEO & Director	3.4yrs	UK£427.17k	0.44% $ 1.5k
Martin Thorp	CFO & Director	5.7yrs	UK£322.02k	0.00018% $ 0.6
Christopher Camarra	Executive Vice President of Communications	2.8yrs	데이터 없음	데이터 없음
Lauren Bor	Head of Commercial Development Division	less than a year	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

경험이 풍부한 관리: TCBP 의 관리팀은 경험 ( 3.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Bryan Kobel	CEO & Director	no data	UK£427.17k	0.44% $ 1.5k
Martin Thorp	CFO & Director	8.7yrs	UK£322.02k	0.00018% $ 0.6
Arlene Morris	Non-Executive Independent Chair	2.8yrs	UK£23.53k	0% $ 0
Mark Bonyhadi	Chairman of Scientific Advisory Board	2.5yrs	UK£23.53k	0% $ 0
A. Culverwell	Non-Executive Independent Director	2.8yrs	UK£23.53k	0% $ 0
Isabelle Riviere	Member of Scientific Advisory Board	2.1yrs	데이터 없음	데이터 없음
Daniel Olive	Member of Scientific Advisory Board	2.1yrs	데이터 없음	데이터 없음
Uma Lakshmipathy	Member of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음
Erin Adams	Member of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음
Blythe Sather	Member of Scientific Advisory Board	2.1yrs	데이터 없음	데이터 없음
Chris Bond	Member of Scientific Advisory Board	2.1yrs	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: TCBP 의 이사회는 경험(평균 재직 기간 2.5 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

TC Biopharm (Holdings) 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

TC Biopharm (Holdings) Plc, Annual General Meeting, Mar 14, 2024

TC BioPharm (Holdings) PLC Appoints Lauren Bor as Head of Commercial Development Division

TC Biopharm (Holdings) Plc, Annual General Meeting, Jun 29, 2023

TC Biopharm Appoints Arlene Morris as New Chair of the Board

TC BioPharm (Holdings) plc Announces the Appointment of Bree Harlin as Chief Clinical Officer

High number of new and inexperienced directors

Recent updates

TC BioPharm Remains Compliant with All Nasdaq Listing Requirements and Continues Trading on the Nasdaq Stock Exchange, Responds to False Social Media Claim

TC BioPharm Remains Compliant with All Nasdaq Listing Requirements and Continues Trading on the Nasdaq Stock Exchange, Responds to False Social Media Claim

TC Biopharm (Holdings) Plc Announces Dosing of 5 New Patients in ACHIEVE

TC BioPharm (Holdings) PLC Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications

TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering.

TC Biopharm (Holdings) Plc has completed a Follow-on Equity Offering in the amount of $2 million.

TC BioPharm (Holdings) PLC Announces Dosing of 6th Patient in ACHIEVE Study in Patients with Acute Myeloid Leukemia

TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering.

TC Biopharm (Holdings) Provides Non-Compliance Update

TC Biopharm (Holdings) Plc Announces Launch of Compassionate Use Program for TCB008

New major risk - Revenue size

TC Biopharm (Holdings) Plc, Annual General Meeting, Mar 14, 2024

TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering in the amount of $3.5 million.

TC BioPharm (Holdings) PLC Appoints Lauren Bor as Head of Commercial Development Division

TC Biopharm (Holdings) Plc Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia

TC Biopharm (Holdings) Plc Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia

New major risk - Share price stability

TC Biopharm (Holdings) Regains Compliance with the Nasdaq Stock Market Listing Rule 5550(b)

TC Biopharm (Holdings) Plc, Annual General Meeting, Jun 29, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

TC Biopharm Appoints Arlene Morris as New Chair of the Board

TC Biopharm (Holdings) Plc Announces Successful Dosing of Final Patient in ACHIEVE Safety Cohort

TC BioPharm (Holdings) plc Announces the Appointment of Bree Harlin as Chief Clinical Officer

TC Biopharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1)

First half 2022 earnings released: EPS: UK£0.93 (vs UK£6.78 loss in 1H 2021)

TC Biopharm (Holdings) Plc announced that it has received $7.35 million in funding

TC Biopharm (Holdings) Plc announced that it expects to receive $7.35 million in funding

Tc BioPharm Begins Dosing Phase 2B Clinical Study Evaluating Its Lead Compound, Omnimmune(R), in Patients with Acute Myeloid Leukemia

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc, Annual General Meeting, Nov 14, 2022

TC Biopharm (Holdings) Plc Announces Additions to Scientific Advisory Board

TC Biopharm (Holdings) Plc, Annual General Meeting, Nov 01, 2022

TC Biopharm (Holdings) PLC Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc has completed a Follow-on Equity Offering in the amount of $4 million.

TC Biopharm Announces Formation of Scientific Advisory Board

TC Biopharm (Holdings) Plc Receives CryoTC Trademark for Proprietary Cell Freezing Process

High number of new directors

TC Biopharm (Holdings) Plc Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T Cells

TC Biopharm (Holdings) Plc Announces Appointment of New Board Members

TC Biopharm (Holdings) Plc has completed an IPO in the amount of $17.54118 million.

No independent directors

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령